CN116096361B - 新型环烯酮化合物或其盐 - Google Patents

新型环烯酮化合物或其盐

Info

Publication number
CN116096361B
CN116096361B CN202180057124.1A CN202180057124A CN116096361B CN 116096361 B CN116096361 B CN 116096361B CN 202180057124 A CN202180057124 A CN 202180057124A CN 116096361 B CN116096361 B CN 116096361B
Authority
CN
China
Prior art keywords
compound
added
mixture
methyl group
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180057124.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN116096361A (zh
Inventor
重野和彦
野间崇央
箱崎敦志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CN116096361A publication Critical patent/CN116096361A/zh
Application granted granted Critical
Publication of CN116096361B publication Critical patent/CN116096361B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
CN202180057124.1A 2020-08-07 2021-08-06 新型环烯酮化合物或其盐 Active CN116096361B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020135328 2020-08-07
JP2020-135328 2020-08-07
PCT/JP2021/029246 WO2022030606A1 (ja) 2020-08-07 2021-08-06 新規なシクロアルケノン化合物又はその塩

Publications (2)

Publication Number Publication Date
CN116096361A CN116096361A (zh) 2023-05-09
CN116096361B true CN116096361B (zh) 2025-10-10

Family

ID=80118163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180057124.1A Active CN116096361B (zh) 2020-08-07 2021-08-06 新型环烯酮化合物或其盐

Country Status (11)

Country Link
US (1) US20230295068A1 (https=)
EP (1) EP4194435A4 (https=)
JP (1) JP7109705B2 (https=)
KR (1) KR20230043923A (https=)
CN (1) CN116096361B (https=)
AU (1) AU2021321705B2 (https=)
BR (1) BR112023001832A2 (https=)
CA (1) CA3188292A1 (https=)
MX (1) MX2023001536A (https=)
TW (1) TWI829001B (https=)
WO (1) WO2022030606A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4477642A4 (en) * 2022-02-09 2026-02-25 Taiho Pharmaceutical Co Ltd CRYSTALLINE FORM OF CYCLOHEXENONE COMPOUND

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228893B1 (en) * 1997-08-13 2001-05-08 Meiji Milk Products Co., Ltd. Cyclohexenone long-chain alcohol and medicament containing same
US20040132829A1 (en) * 2001-02-19 2004-07-08 Masao Miyagawa Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
ES2849425T3 (es) 2016-01-22 2021-08-18 Taiho Pharmaceutical Co Ltd Método de fabricación de alcohol de cadena larga de ciclohexenona de alta pureza
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228893B1 (en) * 1997-08-13 2001-05-08 Meiji Milk Products Co., Ltd. Cyclohexenone long-chain alcohol and medicament containing same
US20040132829A1 (en) * 2001-02-19 2004-07-08 Masao Miyagawa Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ming Chang P. Yeh et al..1,4-Additions of the Highly functionalized Copper Reagents RCu（CN）ZnI•2 BF3 to Trisubstituted Enones： A New BF3 Promoted Cyclization Reaction.《Nanoscale Research Letters》.1988,第29卷(第51期),第6693-6696页，尤其是第6694页合成路线2. *

Also Published As

Publication number Publication date
CA3188292A1 (en) 2022-02-10
TW202216650A (zh) 2022-05-01
US20230295068A1 (en) 2023-09-21
JP7109705B2 (ja) 2022-07-29
TWI829001B (zh) 2024-01-11
MX2023001536A (es) 2023-03-08
BR112023001832A2 (pt) 2023-02-23
WO2022030606A1 (ja) 2022-02-10
KR20230043923A (ko) 2023-03-31
JPWO2022030606A1 (https=) 2022-02-10
CN116096361A (zh) 2023-05-09
EP4194435A1 (en) 2023-06-14
AU2021321705B2 (en) 2024-02-29
AU2021321705A1 (en) 2023-03-09
EP4194435A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
EP2844637B1 (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
TWI690511B (zh) 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑
WO2024032747A1 (zh) 三环类化合物及其医药用途
CN102958937B (zh) 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物
CN110128432B (zh) 含氮三环化合物及其在药物中的应用
CZ20033296A3 (cs) Benzoylsulfonamidy a sulfonylbenzamidiny jako protinádorové sloučeniny
EP3153511B1 (en) 2-acylaminothiazole derivative for use in the prevention or treatment of bladder/urinary tract diseases
WO2019149228A1 (zh) 取代咪唑甲酸酯类衍生物及其用途
CN116096361B (zh) 新型环烯酮化合物或其盐
US12274694B2 (en) Dizocilpine derivatives as peripheral NMDA receptor antagonists
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
HK40087434B (zh) 新型环烯酮化合物或其盐
HK40087434A (zh) 新型环烯酮化合物或其盐
CN113149894B (zh) (e)-3-芳杂环基丙-2-烯酸衍生物的制药用途
US12030835B2 (en) Substituted amide compounds useful as farnesoid X receptor modulators
CN114957270A (zh) 一种s（+）-普拉洛芬衍生物及其制备方法与用途
CN111138422B (zh) 一种用于防治红斑狼疮的药物及其制备方法
CN118684668A (zh) 螺环类化合物及其药物组合物、制备方法和用途
CN111233837A (zh) 一种缩氨基硫脲的化合物及其制备方法和用途
CN119059989A (zh) Urat1抑制剂及其制备方法和用途
TW202604902A (zh) 作為電壓閘控鈉通道抑制劑的化合物及其應用
JPS6219430B2 (https=)
HK1203477B (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
HK1182699B (en) Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087434

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant